Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

NCT03413384 is registered in ClinicalTrials.gov with BrainX Corporation as lead sponsor.

NCT NCT03413384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03413384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
Lead sponsor
BrainX Corporation
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2019
Completion date
March 13, 2026
Enrollment
100 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease dementia